

## Supplemental Figure Legends

### Figure S1, related to Figure 1. Hyperplasia of the small intestine in *Lpcat3*-deficient mice.

- (A) Expression of *Lpcat3* in small intestine and colon of F/F and *CreERT2* mice (n=6,7 mice/group).
- (B) Body weight change in tamoxifen-injected F/F and *CreERT2* mice (n=5,7 mice/group).
- (C) Small intestine length of tamoxifen-injected F/F and *CreERT2* mice (n=8,9 mice/group).
- (D) Representative histology of Duodenum from F/F and *CreERT2* mice 3 weeks after tamoxifen injection.
- (E) Quantification of crypt number and villus/crypt length ratio in Duodenum and Jejunum from F/F and *CreERT2* mice 3 weeks after tamoxifen injection (n=4 mice/group).
- (F) Representative histology of Duodenum and Jejunum from female *CreERT2* mice with/without tamoxifen injection for 8 weeks (n=5 mice/group).
- (G) Expression of *Lpcat3* in Duodenum from F/F and *CreERT2* mice 14 weeks after tamoxifen injection (n=6,7 mice/group).
- (H) Representative images of intestines from F/F and *CreERT2* mice 14 weeks after tamoxifen injection.
- (I) Small intestine length of F/F and *CreERT2* mice 14 weeks after tamoxifen injection (n=6,7 mice/group).
- (J) Representative images of Id1 immunostaining in colon of F/F and *CreERT2* mice 3 weeks after tamoxifen injection.

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test (A, B, C, E, G, and I). \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ . Scale bars: 20  $\mu\text{m}$  (J), 100  $\mu\text{m}$  (F) and 200  $\mu\text{m}$  (D).

**Figure S2., related to Figure 1. Loss of Lpcat3 impairs ISC differentiation.**

(A) Representative images of immunofluorescence (IF) staining and quantification of Lysozyme positive Paneth cells in Jejunum from F/F and *CreERT2* mice 3 weeks after tamoxifen injection (~100 crypts from 4 mice/group).

(B) Representative images of Periodic Acid Schiff (PAS) staining and quantification of goblet cells in Jejunum as in A (~100 villi from 4 mice/group).

(C) Representative images of IF staining and quantification of Chromogranin A (ChgA) positive enteroendocrine cells in Jejunum as in A (~50 villus-crypt units from 4 mice/group).

(D) Expression of cytokines in F/F and *CreERT2* intestines (n=5 mice/group).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test. \*\*\*\*

$P < 0.0001$ , n.s. not significant. Scale bars: 50  $\mu\text{m}$  (A and C), and 100  $\mu\text{m}$  (B).

**Figure S3, related to Figure 2. Lipidomic analysis of crypts and PGE2 production in Jejunum from control and Lpcat3-deficient mice.**

(A-B) ESI-MS/MS analysis of the abundance of PC species and total PC in crypts isolated from F/F and *CreERT2* mice.

(C) Expression of Cox-1 and Cox-2 in crypts (n=10 F/F mice, and 9 *CreERT2* mice) and intestines (n=8 F/F mice, and 6 *CreERT2* mice).

**(D)** PGE2 concentration in F/F and *CreERT2* Jejunums determined by ELISA assay ((n=12 F/F mice, and 10 *CreERT2* mice).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

**Figure S4, related to Figure 3. Effects of *Lpcat3* deficiency on expression of the SREBP-1, Wnt, Notch, Yap and PPAR $\delta$  pathways.**

**(A-C, E)** Expression of selective genes in Wnt (A), Notch, Yap (B), PPAR $\delta$  (C) and fatty acid biosynthetic pathways (E) in F/F and *CreERT2* crypts analyzed by realtime RT-PCR (n=11 F/F mice, and 9 *CreERT2* mice).

**(D)** Expression of selective genes in cholesterol biosynthesis in F/F and *CreERT2* colons (n=6,7 mice/group)

**(F)** Expression of selective genes in F/F and *CreERT2* organoids treated with vehicle (DMSO) or 4-hydroxytamoxifen (4-OHT, 100 nM) (n=7~8).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test (A-E) and one-way ANOVA (F). \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

**Figure S5, related to Figure 4. Inhibition of cholesterol biosynthesis reduces Id1+ progenitor cells in *Lpcat3*-deficient intestine.**

**(A)** Representative images of Ro48 treated organoids in the presence of cholesterol or epicholesterol.

**(B)** Quantification of villus length in Jejunum of control and *Lpcat3* deficient mice treated with vehicle or Ro48 (~20-50 villi per mouse, 3 *CreERT2* and 2 F/F mice/group).

(C) Representative images of IHC staining of *Olfm4* positive ISC in Jejunum of control mice treated with vehicle or Ro48.

(D-E) Representative images of immunostaining and quantification of Lysozyme positive Paneth cells (D) and PAS positive goblet cells (E) in Jejunum of *CreERT2* mice treated with vehicle or Ro48 (n=3 mice/group, ~40 crypts and ~100 villi per mouse).

(F) Representative images of IHC of cleaved caspase 3 in Jejunum of *CreERT2* mice treated with vehicle or Ro48 (n=3 mice/group).

(G) Representative images of immunostaining and quantification of Id1-positive progenitor cells in Jejunum of *CreERT2* mice treated with vehicle or Ro48 (n=3 mice/group, ~30 crypts per mouse).

Values are means  $\pm$  SEM. Statistical analysis was performed with two-way ANOVA (B) and Student's t test (G). \*\*\*\*  $P < 0.0001$ . Scale bars: 20  $\mu\text{m}$  (C and G), 50  $\mu\text{m}$  (D and F), 100  $\mu\text{m}$  (E), and 200  $\mu\text{m}$  (A).

**Figure S6, related to Figure 5. Overexpression of *Srebf2* increases Id1-positive progenitor cells.**

(A) Free cholesterol content in crypts isolated from chow and cholesterol diet fed mice.

(B) Representative images of immunostaining and quantification of Id1 positive progenitor cells in Jejunum of WT and *Srebf2* Tg mice (n=4 mice/group, ~50 crypts per mouse).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test. \*  $P < 0.05$ , \*\*\*\*  $P < 0.0001$ .

**Figure S7, related to Figure 6. Analysis of inflammation and gene expression in *Apc*<sup>min/+</sup> mice.**


(A-B) Representative images of immunostaining of Ly6G and F4/80 in F/F and *CreERT2*, and *Lpcat3*<sup>F/F</sup>, *CreERT2*, *Apc*<sup>min/+</sup> and *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> intestines.

(C) Expression of cytokines in *Lpcat3*<sup>F/F</sup>, *CreERT2*, *Apc*<sup>min/+</sup> and *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> intestines (n=6-7 mice/group).

(D) Expression of selective genes in cholesterol biosynthetic pathway WT and *Apc*<sup>min/+</sup> Jejunums, analyzed by real-time RT-PCR (n=6-7 mice/group).





(E) Hematocrit in *Apc*<sup>min/+</sup> and *Srebf2* Tg, *Apc*<sup>min/+</sup> mice.

Values are means ± SEM. Statistical analysis was performed with Student's t test. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*\*  $P < 0.0001$ .





Wang Suppl. Fig. 1, related to Figure 1










**A****B****C****D**











Supplemental Table 1, related to STAR methods. Primer sequences used.

Primer	Sequence
36B4 F	GGCCCTGCACTCTCGCTTTC
36B4 R	TGCCAGGACGCGCTTGT
Actin F	GGCTGTATTCCCCTCCATCG
Actin R	CCAGTTGGTAAACAATGCCATGT
Lpcat3 F	GGC CTC TCA ATT GCT TAT TTC A
Lpcat3 R	AGC ACG ACA CAT AGC AAG GA
Srebf2 F	ACCTAGACCTCGCCAAAGGT
Srebf2 R	GCACGGATAAGCAGGTTTGT
Hmgcr F	CTT GTG GAA TGC CTT GTG ATT G
Hmgcr R	AGC CGA AGC AGC ACA TGA T
Hmgcs1 F	GCCGTGAACTGGGTCGAA
Hmgcs1 R	GCATATATAGCAATGTCTCCT
Mvd F	ATGGCCTCAGAAAAGCCTCAG
Mvd R	TGGTCGTTTTAGCTGGTCCT
Fdps F	GGAGGTCCTAGAGTACAATGC
Fdps R	AAGCCTGGAGCAGTTCTACAC
Lss F	TCGTGGGGGACCCTATAAAAC
Lss R	CGTCTCCGCTTGATAATAAG
Cyp51 F	GACAGGAGGCAACTTGCTTTC
Cyp51 R	GTGGACTTTTCGCTCCAGC
Idi1 F	ACCAGCCATCTTGATGAAAAA
Idi1 R	CAGCAACTATTGGTGAAACAA
Nsdhl F	TCATGGTGAATCAAAGCGAGG
Nsdhl R	CCGGGGGTATCAAAGCCTTG
Mvk F	GCTGTGGTCGGAACCTTCC
Mvk R	CCTTGAGCGGGTTGGAGAC
Pmvk F	AAAATCCGGGAAGGACTTCGT
Pmvk R	AGAGCACAGATGTTACCTCCA
Fdft1 F	ATGGAGTTCGTC AAGTGTCTA
Fdft1 R	CGTGCCGTATGTCCCCATC
Il-1b F	AGA AGC TGT GGC AGC TAC CTG
Il-1b R	GGA AAA GAA GGT GCT CAT GTC C
Tnf alpha F	TGC CTA TGT CTC AGC CTC TTC
Tnf alpha R	GAG GCC ATT TGG GAA CTT CT
Mcp-1 F	CATCCACGTGTTGGCTCA
Mcp-1 R	GATCATCTTGCTGGTGAATGA
iNOS F	GCAGCTGGGCTGTACAAA
iNOS R	AGCGTTTTCGGGATCTGAAT
Il-6 F	GCT ACC AAA CTG GAT ATA ATC AAG A
Il-6 R	CCA GGT AGC TAT GGT ACT CCA GAA
Fasn F	TGCTCCAGCTGCAGGC
Fasn R	GCCCGGTAGCTCTGGGTGTA
Srebp1c F	GGAGCCATGGATTGCACATT
Srebp1c R	GGCCCGGGAAGTCACTGT
Srebp1a F	GGCCGAGATGTGCGAAT

Srebp1a R	TTGTTGATGAGCTGGAGCATG
Elovl6 F	CAGCAAAGCACCCGAACTA
Elovl6 R	AGGAGCACAGTGATGTGGTG
Scd1 F	CGAAGTCCACGCTCGATCTC
Scd1 R	TGTGGGCCGGCATGAT
Lgr5 F	GGGCGTTAAGTCCACTGTGT
Lgr5 R	CGAACACCTGCGTGAATATG
Ascl2 F	AAGCACACCTTGACTGGTACG
Ascl2 R	AAGTGGACGTTTGCACCTTCA
Axin2 F	TGACTCTCCTTCCAGATCCCA
Axin2 R	TGCCACACTAGGCTGACA
Cox-1 F	GTGCTGGGGCAGTGTGGAG
Cox-1 R	TGGGGCCTGAGTAGCCCGTG
Cox-2 F	CAAGGGAGTCTGGAACATTG
Cox-2 R	ACCCAGGTCCTCGTTATGA
Hes1-F	ACACCCGACAAAACCAAAGAC
Hes1-R	AATGCCGGGAGCTATCTTTC
Atoh1-F	GCCTTGCCGGACTCGTCTCTC
Atoh1-R	TCTGTGCCATCATCGTGTTAGGG
CTGF-F	AGACCTGTGCCTGCCATTAC
CTGF-R	AGCCCATGTCTCCGTACATC
Cyr61-F	AGAGGCTTCTGTCTTTGGC
Cyr61-R	CCAAGACGTGGTCTGAACGA
Birc5-F	GAACCCGATGACAACCCGAT
Birc5-R	CTCCTTTGCAATTTTGTCTTGGC
Yap-F	ATTTCCGGCAGGCAATACGGA
Yap-R	CATCCTGCTCCAGTGTAGGC
Notch1-F	CCCTTGCTCTGCCTAACGC
Notch1-R	GGAGTCTGGCATCGTTGG
Notch2-F	GGAATGGTGGCAGAGTTGAT
Notch2-R	TCGCCTCCACATTATTGACA
Notch3-F	GGACAAGATGCACTGGGAAT
Notch3-R	AGTCTCTTGGCCTCTGGACA
Notch4-F	TTCTCGTCCTCCAGCTCATT
Notch4-R	CCACTCCATCCTCATCCACT
Jag2-F	GCACCTGCACACATAACACC
Jag2-R	TTGACGCCATCAACACAGAT
Dll1-F	GGCTTCTCTGGCTTCAACTG
Dll1-R	CACCGGCACAGGTAAGAGTT
Dll4-F	ACCTTTGGCAATGTCTCCAC
Dll4-R	GTTTCTGGCGAAGTCTCTG
Taz-F	GAAGGTGATGAATCAGCCTCTG
Taz-R	GTCTGAGTCGGGTGGTTCTG
Apc F	TGAGTGCCTTATGGAACCTGT
Apc R	CTCCGGTAAGTGAGGGTGC
Ccnd1 F	GAATCTGCCCTGTGACATGAAA
Ccnd1 R	CCATGGTGTGTCAACCAGAAAT
Id2 F	GACAGAACCAGGCGTCCA
Id2 R	AGCTCAGAAGGGAATTCAGATG

Jun F	GAAAAGTAGCCCCAACCTC
Jun R	GGGACACAGCTTTCACCCTA
Jag1 F	GCTTCGGCTCAGGGTCTAC
Jag1 R	GGCGAAACTGAAAGGCAGTA
c-Myc F	GCACAAGCTCACCTCTGAAAAGGAC
c-Myc R	CTCACGAGAGATTCCAGCTCCTCC
Acadm F	TTACCGAAGAGTTGGCGTATGG
Acadm R	TGCGGAGGGCTCTGTAC
Acadl F	CTCCCTGCGCTCCTGAG
Acadl R	AAAATGTCATGCTCCGAGGAAAAG
Acadvl F	GCCGACACACAACCTTTG
Acadvl R	CCGAGCCGACTGCATCTC
Fabp1 F	CCA TGA CTG GGG AAA AAG TC
Fabp1 R	GCC TTT GAA AGT TGT CAC CAT
Ppard F	CTAAGCACATCTACAACGCCTACCT
Ppard R	GCCTGCCACAGTGTCTCGAT
Cpt1a F	CCGCCAATTCCAAAAAGTAAC
Cpt1a R	CATTTGGTTTGTATCACTAGA
Hmgcs2 F	GCAGTGACAAACAGAACAACTTATACAA
Hmgcs2 R	GACCCCTGAAGGCCTCTAGG
Acox1 F	TCGAAGCCAGCGTTACGAG
Acox1 R	ATCTCCGCTCTGGGCGTAGG